top of page

“Simone participated as invited panelist at the IWCPH in Liverpool on the role of modeling and simulation in advancing long-acting injectable products.”

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2024 | AME (academicmedicaleducation.com)

image.png

"SAAM II may not be opening because of an interference caused by McAfee antivirus software. According to our recent investigations, a McAfee update has been found to block SAAM II from launching. To resolve this, you can create an exception for SAAM II within McAfee's settings."

459dfb0e-0b4f-4146-9670-159e2697f070.JPG

​
"Simone is invited to speak at the 25th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiretroviral Drugs in Liverpool on 18-19 September"Title of the presentation "Modelling design and validations for complex Long-Acting Medicines"

Title of the presentation "Modelling design and validations for complex Long-Acting Medicines"

AntiviralPK.png



On Tuesday, July 23, Simone discussed the topic B8 Antiretroviral therapies and clinical issues in neonates, infants and children

Poster Exhibition
A novel physiologically-based pharmacokinetic (PBPK) model to guide pediatric dosing for a long-acting triple-drug-in-one injectable product candidate TLC-ART-101 (lopinavir/tenofovir/ritonavir)

Nanomath is pleased to inform you that it will participate again this year in the PAGE (Population Approach Group Europe) 2024 event, which will be held June 26-28, 2024 in Rome, Italy. 

page-meeting-2024.jpg
7bac32e3-f4b4-4f4e-a0bf-182d98a6fb16.JPG

Simone conducted a SAAM II workshop at the University of Colorado Anschutz

image001.png

Simone has presented at CROI in Denver about how modeling can provide more thought-through long-acting injectable solutions in children

https://www.croiconference.org/

New study out on drug-drug interaction and multiple dosing for long-acting injectables of nanoparticle

Screenshot 2024-03-01 070642.png

Simone conducted a SAAM II workshop at the University of Buffalo School of Pharmacy

Schermata 2023-10-06 alle 15.03.06.png

Directly from 31st PAGE Meeting 2023, second day of proceedings

Nanomath is pleased to inform you that it will be attending this year's PAGE (Population Approach Group Europe) 2023 event, which will take place from June 27 to June 30, 2023, in A Coruña, Spain. 

SAAM II: Selected Software Use Cases in Modern PK-PD Data Analysis

Journal of Pharmaceutical Sciences

Outstanding early career scientists for 2022

Immagine 2023-01-18 111802.png

Simone will speak about PBPK and nanoformulation in Seattle 

February 18, 2023

Directly from AAPS 2022 PHARMSCI 360 Boston Convention & Exhibition Center.
Boston, MA

October 16-19, 2022

Unknown.jpeg

Emerging Role of Systems Pharmacology, Long-acting, & Targeted Drug-combination Tech in Making Therapeutic & Health Impact

Monday, October 2022            9-9:30 & 10-10:30 AM

Rethinking the Role of Clinical Pharmacology in a Systems Perspective to Accelerate Small Molecules (Entry, Protease and Polymerase Inhibitors) Development

Monday, October 17, 2022        3:45 PM – 4:00 PM

aaaaaaaaaa.png

Two years anniversary from our President Interview at TG Leonardo in Italy. Those days marked the start of the pandemic. The interview had great relevance in Italy where it got more than 2 million view.

https://www.youtube.com/watch?v=7BpQthHGU0I

March 9th, 2022

Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism
 

Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
 

https://www.sciencedirect.com/science/article/pii/S0022354921005529?dgcid=coauthor

​

January 31th, 2022

​

Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism
 

Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture
 

https://www.sciencedirect.com/science/article/abs/pii/S0022354921005475?dgcid=coauthor

​

December 9th, 2021

​

Here an example of what we can offer. FDA Approves a New Dose of #INGREZZA (#Valbenazine) for Treatm. 
The development program for this sNDA was facilitated via meetings under the Prescription Drug User Fee Act (PDUFA) VI Model-Informed Drug Development (MIDD) Paired Meeting Pilot Program. MIDD is an approach that involves developing and applying exposure-based, biological, and statistical models derived from preclinical and clinical data sources to inform drug development and decision-making. It aims to integrate information from diverse data sources to help decrease uncertainty and lower failure rates and to develop information that cannot or would not be generated experimentally. For additional information on the MIDD Paired Meeting Pilot Program, please visit https://go.usa.gov/xdtdP.



May 21th, 2021
 

2020-12-10-covid-hero-graphicv2.jpeg

Supporting the Development of Long-acting HIV Injectables via Pharmacokinetic Modeling.


Simone Perazzolo UW Pharmaceutics Research Associate in the Rodney Ho Lab, will be presenting on his research,

“Supporting the Development of Long-acting HIV Injectables via Pharmacokinetic Modeling.”

(Abstract attached) 

 

 

​

November 9th, 2020
 

image004.png

UW Pharmaceutics engineer discusses how HIV research could impact COVID-19 remendis











Rai Italyt Tg3 March 12th, 2020

bottom of page